|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
AB Foundation |
|---|---|
| Information provided by: | AB Foundation |
| ClinicalTrials.gov Identifier: | NCT00373568 |
Purpose
Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis
| Condition | Intervention | Phase |
|---|---|---|
|
Leishmaniasis |
Drug: miltefosine: 2.5 mg/kg/day for 42 days |
Phase I Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Miltefosine (42 Days) for Mucosal Leishmaniasisi |
| Estimated Enrollment: | 25 |
| Study Start Date: | April 2005 |
| Estimated Study Completion Date: | December 2007 |
Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi
Eligibility| Ages Eligible for Study: | 12 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | 05--01 |
| Study First Received: | September 7, 2006 |
| Last Updated: | September 7, 2006 |
| ClinicalTrials.gov Identifier: | NCT00373568 |
| Health Authority: | Bolivia: Ethics Committee |
|
mucosal miltefosine |
|
Leishmaniasis, Mucocutaneous Leishmaniasis Protozoan Infections Skin Diseases, Infectious Skin Diseases |
Clotrimazole Miconazole Miltefosine Tioconazole Parasitic Diseases |
|
Anti-Infective Agents Antiparasitic Agents Antiprotozoal Agents Skin Diseases, Parasitic Antineoplastic Agents |
Antifungal Agents Therapeutic Uses Sarcomastigophora Infections Mastigophora Infections Pharmacologic Actions |
